Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CET
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at kristin.jones@dowjones.com

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
12/07 DOES IMMUNOMEDICS, INC. (NASDAQ : IMMU) New Candidate IMMU-140 Stand A Chance Of..
12/06 Immunomedics Introduces New Antibody-Drug Conjugate at Annual Meeting of Amer..
11/29 IMMUNOMEDICS : venBio Responds to Immunomedics’ Postponement of Annual Mee..
11/28 IMMUNOMEDICS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Ye..
11/28 Immunomedics Postpones 2016 Annual Meeting of Stockholders
11/22 IMMUNOMEDICS : venBio Comments on its Recent Nomination of Four Highly-Qualified..
11/21 5 TOP NASDAQ BIOTECH STOCKS : Ocular Therapeutix Gains Near 60 Percent
11/19 IMMUNOMEDICS : Comments on Receipt of Director Nominations
11/18 Immunomedics Comments on Receipt of Director Nominations
11/16 IMMUNOMEDICS : Expands Antibody-Drug Conjugate Program to Potentially Address Mo..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/06 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
12/06 New ADC from Immunomedics shows significant anti-tumor effect without excessi..
12/06 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
11/29 Small Caps Biggest Winners
11/03 Immunomedics' (IMMU) CEO Cynthia Sullivan on Q1 2017 Results - Earnings Call ..
Advertisement
Financials ($)
Sales 2017 21,6 M
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 18,1x
Capi. / Sales 2018 7,71x
Capitalization 391 M
More Financials
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,50 $
Spread / Average Target 49%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Cynthia L. Sullivan President, Chief Executive Officer & Director
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President-Finance
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.20.20%391
QUINTILES IMS HOLDINGS..14.10%19 286
INCYTE CORPORATION-7.21%18 957
CELLTRION, INC.--.--%9 997
LONZA GROUP AG9.20%9 261
SEATTLE GENETICS, INC.44.54%9 183
More Results